Rybrevant Faspro won accelerated approval for recurrent or metastatic HNSCC after a trial showed a 42% response rate in previously treated patients.
|Articles|October 1, 2009
Top drivers of costs in 2010
State of the Industry survey results
Advertisement
The former director of the Michigan Department of Human Services and executive at Blue Cross Blue Shield of Michigan, she says medical technology encompasses new procedures, pharmaceuticals and medical devices.
Unlike in most industries, where new technology lowers costs, healthcare innovations often lead to more expense, Udow-Phillips says. New devices and approaches can lead to more diagnostics as well. Offering healthcare coverage to the previously uninsured and underinsured also will increase demand for costlier services.
The Agency for Healthcare Quality & Research is in the process of doling out $300 million in federal stimulus funds to support comparative effectiveness research with the caveat that research should be directed toward discovery of comparative clinical quality, not costs. The cost/value proposition will undoubtedly be weighed separately by private payers and used for coverage decisions.
Advertisement
Related to this article
David Feldshon, M.D., a Yale gastroenterologist who still performs endoscopy two days a week at 75, discusses his approach to MASLD and life outside the clinic.
Researchers in Lyon, France, conducted a retrospective cohort study of intensifying the dosing of biologics such as Humira, adding oral antibiotics, or both as ways to boost the response of patients with hidradenitis suppurativa.
Expect Democrats to flex their oversight powers even if President Donald Trump’s veto power blocks their efforts to reverse Medicaid cuts or restore enhanced ACA subsidies. The administration’s most-favored-nation policies and HHS Secretary Kennedy will probably be in the hot seat.
Health plans should be using data, digital tools and human support to identify potential disruptions early, and whether a member is changing plans or managing a new health condition, the experience should feel guided rather than overwhelming.
Pretax adjusted income from operations from Express Scripts, Cigna's pharmacy benefit manager, fell by 21.5% compared with the third quarter of 2025, while income from operations of its specialty drug business jumped by 15%.
Annesha White, Pharm.D., M.S., Ph.D., and Fredrick Manasseh, Pharm.D., MBA, BCGP, explain where AI helps managed care pharmacy, where bias creeps in and what skills pharmacists need to oversee it.
Teva’s Weltruza delivers olanzapine monthly under the skin, with no loading doses, oral supplementation or post-injection monitoring required.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
WHO adds two Bundibugyo vaccines to Ebola trial in the DRC
2
Cigna’s third-quarter earnings show a drop in income from its pharmacy benefit business
3
Christopher Stanley, M.D., MBA, on culture change and implementing value-based care
4
After a 10-year gap, FDA approves new option for pretreated head and neck cancer
5